Compare PXED & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | CRVS |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | 3400 | 37 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2016 |
| Metric | PXED | CRVS |
|---|---|---|
| Price | $33.11 | $13.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $44.29 | $30.17 |
| AVG Volume (30 Days) | 82.1K | ★ 1.3M |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $3.71 |
| 52 Week High | $38.19 | $26.95 |
| Indicator | PXED | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 55.39 |
| Support Level | $28.40 | $12.95 |
| Resistance Level | $33.05 | $14.00 |
| Average True Range (ATR) | 1.34 | 0.68 |
| MACD | 0.07 | 0.28 |
| Stochastic Oscillator | 91.44 | 79.93 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.